Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...
Drug manufacturer Novo Nordisk announced a new experimental weight-loss pill to treat obesity in development called amycretin ...
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
The drug, called amycretin, helped volunteer patients lose a whopping 13 percent of their body weight over just 12 weeks. That means the new pill may be even more effective than the company's ...